Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Treasury Shares (2016 - 2025)

Catalyst Pharmaceuticals' Treasury Shares history spans 9 years, with the latest figure at $752626.0 for Q4 2025.

  • For Q4 2025, Treasury Shares rose 6.16% year-over-year to $752626.0; the TTM value through Dec 2025 reached $752626.0, up 6.16%, while the annual FY2025 figure was $752626.0, 6.16% up from the prior year.
  • Treasury Shares reached $752626.0 in Q4 2025 per CPRX's latest filing, up from $708960.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.0 million in Q4 2022 to a low of -$2.2 million in Q4 2021.
  • Average Treasury Shares over 4 years is $329.4, with a median of $387980.0 recorded in 2021.
  • Peak YoY movement for Treasury Shares: plummeted 1037.02% in 2021, then soared 145.28% in 2022.
  • A 4-year view of Treasury Shares shows it stood at -$2.2 million in 2021, then soared by 145.28% to $1.0 million in 2022, then fell by 29.1% to $708960.0 in 2024, then increased by 6.16% to $752626.0 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Treasury Shares are $752626.0 (Q4 2025), $708960.0 (Q4 2024), and $1.0 million (Q4 2022).